Market research
SCPH Scpharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 304M
- P/E ratio
- Not available
- Analyst target
- 5.675
- Dividend yield
- Not available
- Beta
- 0.3
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8106481059
- Market cap
- 304M
- P/E ratio
- Not available
- Analyst target
- 5.675
- Dividend yield
- Not available
- Beta
- 0.3
About
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. As of October 7, 2025, scPharmaceuticals Inc. operates as a subsidiary of MannKind Corporation.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SCPH discussion.
5 years, 4 months ago
scPharmaceuticals Inc is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
scPharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 45.6% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 13.8% to $-5M since the same quarter in the previous year.
Based on the above factors, scPharmaceuticals Inc gets an overall score of 2/5.